57 results about "Decompensation" patented technology

Systems and methods of detecting an impending cardiac decompensation of a patient measure an electrocardiogram signal of the patient. An incidence of cardiac arrhythmias is determined from the electrocardiogram signal. A risk of impending decompensation is determined in response to the incidence of cardiac arrhythmias. In many embodiments, the impending decompensation can be detected early enough to avoid, or at least delay, the impending decompensation, such that patient trauma and/or expensive ICU care can be avoided. Although embodiments make specific reference to monitoring electrocardiogram and other physiological signals with an adherent patch, the system methods and devices are applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implanted sensors for extended periods.

Systems, devices and methods provide for evaluation of heart failure symptoms. Sensor data associated with one or more symptoms of heart failure are acquired and trended. Statistical features, such as slope, are extracted from the data trend in a moving window and are used to develop a cumulative sum. The cumulative sum is compared to a threshold value or V-mask to detect a shift in cumulative sum indicating changes in heart failure symptoms. A shift beyond the threshold value may trigger an alert or implementation of therapy.

Systems and methods of monitoring a patient. Exemplary methods include receiving sensor data associated with the patient from a plurality of sensors of a patient monitoring device and determining whether the sensor data satisfies one or more trigger conditions. For each of the trigger conditions satisfied, one or more messages are sent to at least one of the patient monitoring device and an external computing device for display thereby to at least one of the patient, a caregiver, and a support person. Satisfaction of one or more of the trigger conditions may indicate the patient has edema and/or is trending toward decompensation. The sensor data may have been collected from a heart rate sensor, an oximeter, an accelerometer, and/or a sensor configured to detect a distance around a limb of a patient. In some embodiments, the trigger conditions are provided by the patient, caregiver, and/or support person.

A system to monitor heart sounds, such as to detect a worsening condition of heart failure decompensation. The system comprises a medical device that includes an implantable multi-axis heart sound sensor, operable to produce, for each of at least two nonparallel axes, an electrical signal representative of at least one heart sound, the heart sound associated with mechanical activity of a patient's heart. The device further includes a controller circuit coupled to the heart sound sensor. The controller circuit measures components of the heart sound that respectively correspond to each of the axes.

Method and device for the diagnosis and therapy of chronic heart failure comprising continuous monitoring of the patient and continuous determination of significant decompensation parameters during a sample period of normal patient life, recording the data determined, continuously monitoring these data during therapy, comparing the memorized data with those determined during the same time span of the sample period and comparing the duration of periods in which decompensation is present with the total duration of those periods during which decompensation is absent or conforms to that determined during the sample period.

The system described herein collects patient data passively and non-passively via onboard and external sensors, and combines the data with past clinical history to generate digital biomarkers. The collected data can also be further combined with other data generating systems to more accurately predict disease exacerbations. The system monitors the digital biomarkers in real-time, and can detect a change in the disease state prior to clinical decompensation and suggest pre-emptive intervention. The system enables a patient to be treated early in the clinical timeline when the disease exacerbation is at the subclinical level rather than waiting until the disease exacerbation reaches the clinical level. Acting when the exacerbation is at the subclinical level enables preemptive treatment rather than reactive treatment, which is often more cost effective while improving clinical outcomes. The system is able to make the predictions by detecting subclinical changes in digital biomarkers that are generated from respiratory, cardiac, patient reported symptoms, user behaviors, and environmental triggers.

Devices and systems provide methods of detecting a heart failure condition of a patient that may be based on one or more respiratory parameters of a patient. In an example embodiment, a monitoring device determines one or more heart failure condition indicators based on a measure of the patient respiratory airflow and/or a measure of treatment pressure. Respiratory parameters such as respiration rate, hypopneas, apneas, Cheyne-Stokes breathing patterns or apnea-hypopnea counts may be compared to thresholds that are selected to represent a change in the condition of a heart failure patient such as an onset of a decompensation event. Results of the comparisons may trigger a pressure treatment change and/or one or more warnings or messages to notify a patient or physician of a pending change to the patient's heart failure condition so that the patient may more immediately seek medical attention to treat the heart failure condition.

Embodiments of the invention are related to devices and methods for respiration therapy, amongst other things. In an embodiment, the invention includes a system for providing respiration therapy to a patient, including an implantable device comprising a chronically implanted respiration sensor, the respiration sensor configured to generate a signal indicative of respiration rate of the patient; and an external interface device in communication with the implantable device, the external interface device comprising an output device and configured to deliver respiration therapy to the patient, the respiration therapy comprising one or more breathing prompts generated by the output device. In an embodiment, the invention includes a method for providing respiration therapy to a patient. In an embodiment, the invention includes a method of monitoring a heart failure patient for decompensation events. Other aspects and embodiments are provided herein.

Techniques are provided for use with implantable medical devices for addressing encapsulation effects, particularly in the detection of cardiac decompensation events such as heart failure (HF) or cardiogenic pulmonary edema (PE.) In one example, during an acute interval following device implant, cardiac decompensation is detected using heart rate variability (HRV), ventricular evoked response (ER) or various other non-impedance-based parameters that are insensitive to component encapsulation effects. During the subsequent chronic interval, decompensation is detected using intracardiac or transthoracic impedance signals. In another example, the degree of maturation of encapsulation of implanted components is assessed using impedance frequency-response measurements or based on the frequency bandwidth of heart sounds or other physiological signals. In this manner, impedance-based HF/PE detection systems can be activated as soon as component encapsulation has matured, without necessarily waiting until completion of a preset post-implant maturation interval, often set to forty-five days or more.

Techniques are provided for use by an implantable medical device or diagnostic sensor for detecting and discriminating euvolemia, hypervolemia and hypovolemia. In one example, the device detects a pressure signal within the patient representative of changes in cardiac pressure overall several cardiac cycles. The device generates separate time-domain and frequency-domain representations of the pressure signal and then discriminates among euvolemia, hypervolemia and hypovolemia within the patient based on an analysis of the time-domain and the frequency-domain representations of the signal. Depending upon the capabilities of the device, suitable warnings may be generated to alert the patient or caregiver. Diuretics or other medications can be titrated to address abnormal fluid conditions such as a fluid overload during hypervolemia. Techniques for detecting a pressure alternans pattern indicative of imminent decompensation are also described.

A system which generates a warning signal in the event of looming pulmonary edema and/or looming decompensation. The system has an impedance detection unit for determining impedance values, which represent a transthoracic impedance course, and an impedance analysis unit (78), which is connected to the impedance detection unit. The impedance analysis unit (78) is implemented to determine the degree of modulation for a particular impedance course detected by the impedance detection unit.

Techniques develop models for classification for physical conditions of a subject based on monitored physiologic signal data. The models for classification are determined from data transformed and feature extracted using a Taut-string transformation and in some instances using a further Stockwell-transformation, applied in parallel or in series. Physical conditions, specifying the state of hemodynamic stability and reflective of the cardiovascular and nervous systems, are thus modeled using these techniques.

An apparatus, such as a pressure support ventilator or respiratory monitor, provides operations for a patient, such a patient with heart failure, Chronic Obstructive Pulmonary Disease or other respiratory insufficiency. In some embodiments, the apparatus may detect a respiratory condition, such as a decompensation event and/or exacerbation event, from respiratory parameters. A clinical alert message may be transmitted or displayed for a physician based on the results of query presented to the patient in response to an analysis of the one or more respiratory parameters. In some embodiments, the apparatus generates a potential relapse indicator that may provide a prediction of a risk of an oncoming clinical event such as for evaluating whether to release the patient from a hospital.

The invention relates to a preparation method and application thereof of an acellular conjunctiva matrix used as a tissue engineering corneal scaffold material. The method comprises the following steps: removing cell components in a bulbar conjunctiva first; preparing the acellular conjunctiva matrix; and taking the acellular conjunctiva matrix as a tissue engineering corneal scaffold. A rabbit corneal epithelium or an endothelial cell can form a good cell single layer on the scaffold, can construct a tissue engineering corneal epithelium or endothelium, and can successfully transplant the tissue engineering corneal epithelium or endothelium onto rabbit animal model eyes. The degradation time of the built tissue engineering cornea is longer, rabbit eyes have no obvious immune reject reaction, and the therapeutic effects on the lack of corneal limbus stem cells or the decompensation of the corneal endothelial cell function are obvious. The method and the application thereof have the advantages of simple preparation method, good biocompatibility, low antigenicity, easy growth and proliferation of seed cells, slow degradation, extensive bulbar conjunctiva sources and wide application and development prospects; and the transparency can be maintained all the time in the training process and after transplantation.

The invention discloses a novel Chinese medicinal composition for treating cardiac failure and a preparation method thereof. The Chinese medicinal composition of the invention mainly comprises the following raw material medicaments: kudzu-vine root, tangerine peel, green tangerine peel, immature bitter orange, costustoot, cyperus rotundus, szechwan chinaberry fruit, aspongopus, Chinese eaglewood, cassia bark, medcinal evodia fruit, lesser galangal rhizome, szechuan lovage rhizome, yanhusuo, danshen root, sanchi, turmeric root-tuber, curcuma longa, frankincense, myrrh, safflower, peach seed, motherwort herb, twotooth achyranthes root, common burreed rhizome, zedoary, mix-fried pangolin scales, ginseng, American ginseng, raw raidx astragali, pilose asiabell root, white paeony root, common yam rhizome, Chinese angelica, storax, toad venom, grassleaf sweelflag rhizome, borneol, camphor, musk, Chinese caterpillar fungus, cherokee rose fruit, desertliving cistanche, radix rehmanniae preparata, tuber fleeceflower root, root of straight ladybell, barbary wolfberry fruit, mix-fried turtle shell, mix-fried tortoise plastron, agastache and villous amomum fruit. The Chinese medicinal composition of the invention can be prepared into a normal oral preparation by the common Chinese medicament preparation method. The Chinese medicinal composition can obviously improve tireness and hypodynamia, decompensation, chest distress and dyspnea, cough, wheezing, limb oedema, jugular vein distention and inappetence, and has exact and obvious curative effect and quick response. The Chinese medicinal composition of the invention basically adopts medicinal and edible medicaments specified by the National Formulary to carry out combination, thus, the Chinese medicinal composition has the advantages of low price, basically no toxic or side effects and the like.

The present invention provides methods and compositions for monitoring of subjects suffering from, or being evaluated for, heart failure. A filtered Natriuretic peptide time-series, alone or in combination with other clinical indicia such as weight gain, can be used to estimate a patient's hazard (risk of decompensation). The cumulative integral of Natriuretic peptide concentration can be used to estimate cumulative hazard (risk times exposure) over longer periods of exposure, e.g., 14 day periods, or 30 day periods.

Techniques are provided for use with implantable medical devices for addressing encapsulation effects, particularly in the detection of cardiac decompensation events such as heart failure (HF) or cardiogenic pulmonary edema (PE.) In one example, during an acute interval following device implant, cardiac decompensation is detected using heart rate variability (HRV), ventricular evoked response (ER) or various other non-impedance-based parameters that are insensitive to component encapsulation effects. During the subsequent chronic interval, decompensation is detected using intracardiac or transthoracic impedance signals. In another example, the degree of maturation of encapsulation of implanted components is assessed using impedance frequency-response measurements or based on the frequency bandwidth of heart sounds or other physiological signals. In this manner, impedance-based HF/PE detection systems can be activated as soon as component encapsulation has matured, without necessarily waiting until completion of a preset post-implant maturation interval, often set to forty-five days or more.

Heart monitoring system includes implantable medical device and service center. Implantable medical device includes stimulation pulse generator, ventricular sensing stage, activity sensor, impedance determination unit with a constant current or voltage source to generate sub-threshold measuring current pulses having constant current strength or constant voltage, measuring unit for measuring a voltage corresponding to a current fed through a body, impedance value determination unit connected with measuring unit adapted to determine impedance value for each measuring current pulse, and perform intrathoracic impedance measurement, a control unit adapted to collect data representing values of changes, and initiate data transmission, implant transceiver unit communicating with the service center with a data evaluation module including data trending of stored data with a user interface and said data evaluation module adapted to allow a physician to set for each data trend trigger criteria for decompensation detection and generate a decompensation indicator signal.

The present disclosure pertains to a system configured to predict decompensation in a subject with heart failure. The system comprises one or more hardware processors configured by machine-readable instructions to receive weight information, blood pressure information, and heart rate information about the subject; determine one or more weight parameters, one or more blood pressure parameters, and one or more heart rate parameters based on the received information; and predict decompensation in the subject based on the one or more weight parameters, the one or more blood pressure parameters, and the one or more heart rate parameters. Prior art systems use weight parameters alone for such prediction. However, weight parameters alone are often not predictive of decompensation.

The invention relates to a laurane type sesquiterpene compound or a derivative thereof extracted and separated from a sea plant Laurencia okamurai in the East China Sea, and a preparation method and application thereof. The structural formula of the laurane type sesquiterpene compound or the derivative thereof is shown as above: when R1, R2 and R3 are hydrogen at the same time, the sesquiterpene compound or the derivative thereof is laurinferol, and when R4 is hydrogen, the sesquiterpene compound or the derivative thereof is aplysin. In vitro tests show that the sesquiterpene compound or the derivative thereof has obvious pancreatic lipase inhibition activity and is expected to be applied to preparing medicaments for preventing or treating decompensation diseases including adiposis, diabetes, hyperlipoidemia, fatty liver and the like. The sesquiterpene compound or the derivative thereof can also provide a lead compound for developing the new medicaments for preventing and treating the decompensation diseases, and is significant for developing and utilizing marine biological resources of China.

The invention relates to the detection of electrical and mechanical cardio-vascular activities of a patient, especially to early decompensation detection of congestive heart failure patients (CHF). The device according to the invention comprises a transmitter for transmitting electromagnetic signals of a predefined frequency into the chest of the patient, a Doppler radar sensor 1 for detecting a Doppler radar signal reflected in the patient's chest, and an ECG unit 3 for capturing an ECG signal of the patient's heart. This device allows for simultaneous detection of electrical and mechanical cardio-vascular activities of a patient which can be used in an easy and reliable way and which allow for implementation in a hand-held or wearable device.

The invention provides a medicine composite for treating early liver fibrosis or early hepatocirrhosis decompensation, which is a preparation prepared from the following raw material medicines proportioning by weight: 5-15 parts of rhubarb, 5-15 parts of rhizoma sparganii and 5-15 parts of curcuma zedoary. The invention also provides a preparation method and an application of the medicine composite. The bulk drugs in the medicine are used in combination, have the main functions of eradicating blood stasis and removing the stagnation of food, aim to deal with an emergency, can directly carry out treatment aiming at the cause of a disease, also can quickly improve the exigent symptom of the early hepatocirrhosis decompensation, protect the liver function, eliminate blood stasis, promote tissue regeneration and tonify the body in a discharge way, act as the functions of dissolving turbid urine, lessening the virulence of any pathogenic organism, relieving the stagnation of qi, removing the blood stasis and protecting the liver together, have a synergistic action and are used for treating various diseases of the early liver fibrosis or early hepatocirrhosis decompensation.